Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambien IR
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ambien IR (immediate-release) is a sedative-hypnotic medication containing zolpidem tartrate, a non-benzodiazepine imidazopyridine. It functions as a positive allosteric modulator of the gamma-aminobutyric acid A (GABAA) receptor, specifically targeting the alpha-1 subunit (also known as the BZ1 or omega-1 receptor), which is primarily responsible for sedative effects. Developed by Synthelabo in collaboration with Searle and receiving FDA approval in 1992, Ambien IR is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset. The medication is designed for rapid absorption, reaching peak plasma concentrations approximately 0.9 hours after administration. It is available in 5 mg and 10 mg oral tablets and is classified as a Schedule IV controlled substance.
- Brand names
- Ambien
- Other names
- zolpidem tartratezolpidem
02
Targets
GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)GABRA3 (Gamma-aminobutyric acid type A receptor subunit alpha-3)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on Ambien IR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambien IR.